Preclinical Research with Proteonomix, Inc. (PROT)’s UMK-121 Featured in Oral Presentation at the International Society for Cellular Therapy 18th Annual Meeting

Published: Jun 07, 2012

HAWTHORNE, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announces the oral presentation by Chief Scientific Officer Ian McNiece, Ph.D., of research related to the Company’s UMK-121 technology today at the International Society for Cellular Therapy (ISCT) 18th Annual Meeting underway in Seattle.

Back to news